💥 Gate Square Event: #PostToWinCGN 💥
Post original content on Gate Square related to CGN, Launchpool, or CandyDrop, and get a chance to share 1,333 CGN rewards!
📅 Event Period: Oct 24, 2025, 10:00 – Nov 4, 2025, 16:00 UTC
📌 Related Campaigns:
Launchpool 👉 https://www.gate.com/announcements/article/47771
CandyDrop 👉 https://www.gate.com/announcements/article/47763
📌 How to Participate:
1️⃣ Post original content related to CGN or one of the above campaigns (Launchpool / CandyDrop).
2️⃣ Content must be at least 80 words.
3️⃣ Add the hashtag #PostToWinCGN
4️⃣ Include a screenshot s
Fuhong Hanlin: Grants Alvogen Korea exclusive license for Hans.
Jin10 Data reported on April 25 that Fuhong Hanlin announced that the company has entered into a licensing protocol with Alvogen Korea Co., Ltd., granting it exclusive rights to commercialize Hanshuang (Srilumab injection) in South Korea. Under the protocol, Alvogen Korea will pay an upfront payment of $5 million, with regulatory milestone payments not exceeding $9.5 million, commercial sales milestone payments not exceeding $97.5 million, and tiered royalties calculated based on annual net sales ranging from 18% to 25%. The licensing protocol will take effect from the date of signing and will initially last until the 10th anniversary of the first commercial sale of the licensed product.